Pair page
AOD-9604 with CJC-1295
Mechanism-tag overlap and published literature for AOD-9604 and CJC-1295, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
hgh-c-terminal-fragment-lipolytic
ghrhgrowth-hormone-releasing-hormone-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying AOD-9604 and CJC-1295 have published these mechanism-level observations. Not a co-administration recommendation.
GH-axis secretagogue stack. Combining with AOD-9604 provides full-spectrum hGH-receptor stimulation (endogenous GH pulsatile release via CJC / ipamorelin) plus β3-AR-mediated direct lipolysis (AOD-9604). Conceptually a more integrated fat-loss-plus-recovery protocol than AOD-9604 alone.
Quick facts
AOD-9604
CJC-1295
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2014 | AOD-9604 | Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014;95(1):53-66. PMID: 24105257. (Obesity pharmacotherapy review discussing AOD-9604's Phase 2b failure.) PMID 24105257 | human trial, Phase 2 |
| 2013 | AOD-9604 | Kasim-Karakas SE, Cunningham WM, Tsodikov A. Relation of nutrients and hormones in polycystic ovary syndrome. Obesity Pharmacotherapy: Current Perspectives and Future Directions. 2013. PMC: PMC3584306. (Review describing AOD-9604 Phase 2 results and 2007 program termination.) | human trial, Phase 2 |
| 2007 | AOD-9604 | Metabolic Pharmaceuticals Ltd. Phase 2b OPTIONS clinical trial results: AOD9604 24-week randomized placebo-controlled trial in 536 obese adults. 2007. (Failed primary endpoint. Publicly disclosed in biotech press; led to obesity program termination.) | human trial, Phase 2 |
| 2004 | AOD-9604 | Metabolic Pharmaceuticals Ltd. Phase 2 OBESITY clinical trial results: AOD9604 12-week dose-ranging study in obese adults (0.25, 0.5, 1 mg/day). 2004-2005. (Positive Phase 2 signal at 1 mg/day: 2.6 kg weight loss vs 0.8 kg placebo.) | human trial, Phase 2 |
| — | AOD-9604 | ClinicalTrials.gov. Metabolic Pharmaceuticals AOD9604 Phase 2 / Phase 2b obesity trials registration and results. clinicaltrials.gov. (Trial documentation.) | human trial, Phase 2 |
| 2015 | AOD-9604 | Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PMID: 26132939. (Comparator: GLP-1 agonist obesity therapeutic evidence — the modern standard AOD-9604 fails to meet.) PMID 26132939 | human trial |
| 2012 | AOD-9604 | The effect of AOD9604 on weight loss in obese adults: Results of a randomized, double-blind, placebo-controlled, multicenter study (referenced in Chugh 2012 review). | human trial |
| 2012 | AOD-9604 | Chugh PK, Sharma S. Recent advances in the pathophysiology and pharmacological treatment of obesity. J Clin Pharm Ther. 2012;37(5):525-535. DOI: 10.1111/j.1365-2710.2012.01347.x. (Places AOD-9604 in obesity-pharmacotherapy context.) | human study |
| 2001 | AOD-9604 | Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 117132… PMID 11713213 | preclinical, in vivo |
| 2001 | AOD-9604 | Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1586-1592. PMID: 11673763. (Both hGH and AOD-9604 reduce body weight; AOD does not interact… PMID 11673763 | preclinical, in vivo |
| 2000 | AOD-9604 | Ng FM, Sun J, Sharma L, Libinaki R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11044801. (Foundational mechanistic characterization.) PMID 11044801 | mechanism / discovery |
| — | AOD-9604 | Safety review in the Journal of Obesity & Food Metabolism aggregating six RCTs of AOD-9604 (>900 subjects). (Comprehensive safety database summary.) | review |
| 2006 | CJC-1295 | aidsmap. Lipodystrophy study halted after patient death. July 2006. (Reports the ConjuChem Phase 2 CJC-1295 trial halt.) | human trial, Phase 2 |
| 2010 | CJC-1295 | Alexopoulou O, Abs R, Maiter D. Treatment of adult growth hormone deficiency: who, why and how? A review. Acta Clin Belg. 2010;65(1):13-22. PMID: 20373593. PMID 20373593 | human study |
| 2009 | CJC-1295 | Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19540144. PMID 19540144 | human study |
| 2006 | CJC-1295 | Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805… PMID 16352683 | human study |
| 2006 | CJC-1295 | Abla AA, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E… PMID 16835399 | preclinical, in vivo |
| 2005 | CJC-1295 | Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology.… PMID 15817669 | preclinical, in vivo |
| 2005 | CJC-1295 | Alba M, Fintini D, Bowers CY, Parlow AF, Salvatori R. Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2005;289(5):E762-E767. | preclinical, in vivo |
| 2020 | CJC-1295 | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. | mechanism / discovery |
| 1995 | CJC-1295 | Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA. 1995;92(10):4872-4876. PMID: 7761412. (Parent work on tetrasubstituted GHRH analogs.) PMID 7761412 | mechanism / discovery |
| 2023 | CJC-1295 | Alwatban MZ, Al-Lohedan HA. A review of CJC-1295 as a GHRH analog: Pharmacology and clinical relevance. Drug Des Devel Ther. 2023 (review series). | review |
| 2026 | CJC-1295 | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
| 2025 | CJC-1295 | U.S. Food and Drug Administration. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have AOD-9604 and CJC-1295 been studied together?
Researchers have published mechanistic-level co-administration discussion of AOD-9604 and CJC-1295. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do AOD-9604 and CJC-1295 share?
AOD-9604 and CJC-1295 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of AOD-9604 and CJC-1295?
AOD-9604: Not approved (research). CJC-1295: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on AOD-9604 and CJC-1295?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the AOD-9604 profile and the CJC-1295 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026